Primary osteoporosis and low bone density are bone formation deficits associated with aging and decline in sex hormones, affecting an estimated 55 million adults aged 50 and over in the United States, and resulting in more than 2 million fragility fractures per year and over $20 billion in related costs, which are expected to increase as the population ages. No current treatment is able to safely increase bone formation long-term. Thus, novel, safe and effective treatments for low bone mineral density and osteoporosis are urgently needed. Osteoporosis is hypothesized to arise from the shift of MSC differentiation from osteogenesis to adipogenesis, which comes with the loss of MSC self-renewal/differentiation capacity. Differentiation into adipocytes is triggered by the production of reactive oxygen species (ROS), whereas differentiation to osteoblasts takes place under low ROS conditions. Aging of MSCs results in higher levels of ROS, due to lowered resistance to oxidative stress (OS) and increasing use of oxidative phosphorylation (OxPhos) for metabolism, leading to high levels of adipogenesis. In contrast, MSCs with high differentiation capacity (?youthful? MSCs) are characterized by a primarily glycolytic metabolic state with low OxPhos levels, high resistance to OS, and low ROS, resulting in high osteogenesis. In this Phase I SBIR, AgeX Therapeutics, Inc. proposes to study repression of COX7A1, an electron transport chain subunit critical to OxPhos, as a potential therapeutic approach to treating osteoporosis. We identified COX7A1 as a marker of the highly regenerative embryonic state and glycolytic metabolism. In our preliminary studies in COX7A1-knockout mice and COX7A1-knockdown human umbilical cord MSCs, we showed that COX7A1 repression in MSCs increases glycolysis, improves resistance to oxidative stress and gene expression analysis indicates a shift in lineage commitment away from adipogenesis.
In Specific Aim #1, we will perform in vitro experiments to test whether knock out (KO) of COX7A1 expression in MSCs from post-menopausal women (age 55-60) using CRISPR/Cas9 will rejuvenate the cells? proliferative, regenerative, and differentiation capacity to at least 70% of values for MSCs from normal young female donors (age 20-25).
In Specific Aim #2, we will test whether Cox7A1-KO in mouse MSCs in vivo can confer resistance to bone mineral density loss in the ovariectomized (OVX) mouse model of estrogen-deficient bone loss and normal early age-associated bone loss in mice. After having demonstrated that Cox7A1 KO in bone marrow MSCs can restore function in vitro and reduce bone loss in vivo, we will be able to progress to Phase II and transplant human MSC-COX7A1-KO into the mouse OVX model of osteoporosis. Our long-term goal is to commercialize an autologous osteoporosis therapy using COX7A1 repression.
Osteoporosis and low bone density, which are associated with menopause and aging, affect an estimated 55 million adults in the United States, and result in more than two million fragility fractures per year and over $20 billion in related costs. No current treatment is capable of safely increasing bone formation long-term, and novel, safe and effective treatments for low bone mineral density and osteoporosis are urgently needed. AgeX Therapeutics, Inc. proposes to develop a potential therapy for osteoporosis by rejuvenating the bone-forming potential of bone marrow stem cells.
